読み込み中
PAVmed Inc. operates as a U.S.-based medical technology firm. Its principal commercialized products include CarpX, a percutaneous device designed to address carpal tunnel syndrome. Other key offerings are EsoCheck, an esophageal cell collection device vital for the early detection of esophageal adenocarcinoma and Barrett's Esophagus (BE), and EsoGuard, a specialized bisulfite-converted next-generation sequencing DNA assay. The company's extensive development pipeline further encompasses EsoCure, an esophageal ablation device intended to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; and NextFlo, a disposable infusion platform technology. Also in development are the Veris cancer healthcare platform, which features an intelligent vascular port for combined remote monitoring and data analytics, alongside Veris cardiac monitors. Additional innovations include NextVent single-use ventilators, FlexMO medical circulatory support cannulas, DisappEAR resorbable pediatric ear tubes, and Solys for noninvasive glucose monitoring. Established in 2014, the enterprise originally traded as PAXmed Inc. before rebranding to PAVmed Inc. in April 2015. Its corporate headquarters are located in New York, New York.
前日終値
$2.79
+$0.10 · +3.72%
日中の時刻はETです。市場データは遅延する場合があります。
PAVmed Inc. operates as a U.S.-based medical technology firm. Its principal commercialized products include CarpX, a percutaneous device designed to address carpal tunnel syndrome. Other key offerings are EsoCheck, an esophageal cell collection device vital for the early detection of esophageal adenocarcinoma and Barrett's Esophagus (BE), and EsoGuard, a specialized bisulfite-converted next-generation sequencing DNA assay. The company's extensive development pipeline further encompasses EsoCure, an esophageal ablation device intended to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; and NextFlo, a disposable infusion platform technology. Also in development are the Veris cancer healthcare platform, which features an intelligent vascular port for combined remote monitoring and data analytics, alongside Veris cardiac monitors. Additional innovations include NextVent single-use ventilators, FlexMO medical circulatory support cannulas, DisappEAR resorbable pediatric ear tubes, and Solys for noninvasive glucose monitoring. Established in 2014, the enterprise originally traded as PAXmed Inc. before rebranding to PAVmed Inc. in April 2015. Its corporate headquarters are located in New York, New York.
日中レンジ
現在 $2.79
52週レンジ
現在 $2.79
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
強い売り
バリュエーション
2
著しい割高
センチメント
51
まちまち
リスク
70
高リスク
モメンタム
22
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
PAVmed Inc. operates as a U.S.-based medical technology firm. Its principal commercialized products include CarpX, a percutaneous device designed to address carpal tunnel syndrome. Other key offerings are EsoCheck, an esophageal cell collection device vital for the early detection of esophageal adenocarcinoma and Barrett's Esophagus (BE), and EsoGuard, a specialized bisulfite-converted next-generation sequencing DNA assay. The company's extensive development pipeline further encompasses EsoCure, an esophageal ablation device intended to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; and NextFlo, a disposable infusion platform technology. Also in development are the Veris cancer healthcare platform, which features an intelligent vascular port for combined remote monitoring and data analytics, alongside Veris cardiac monitors. Additional innovations include NextVent single-use ventilators, FlexMO medical circulatory support cannulas, DisappEAR resorbable pediatric ear tubes, and Solys for noninvasive glucose monitoring. Established in 2014, the enterprise originally traded as PAXmed Inc. before rebranding to PAVmed Inc. in April 2015. Its corporate headquarters are located in New York, New York.
日中レンジ
現在 $2.79
52週レンジ
現在 $2.79
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 7.1万 USD | 299.5万 USD | 245.2万 USD | 37.7万 USD | 50万 USD |
| 売上原価 | 32.3万 USD | 603.8万 USD | 642万 USD | 361.4万 USD | 58.5万 USD |
| 粗利益 | −25.2万 USD | −304.3万 USD | −396.8万 USD | −323.7万 USD | −8.5万 USD |
| 研究開発 | 44.92億 USD | 593.2万 USD | 1427.6万 USD | 2533.8万 USD | 1984.7万 USD |
| 販売・一般管理 | 171.67億 USD | 3615.1万 USD | 4853万 USD | 6072.8万 USD | 3431.5万 USD |
| 営業費用 | 2155.4万 USD | 4144.4万 USD | 6482.7万 USD | 8785万 USD | 5430.8万 USD |
| 受取利息 | 2.9万 USD | 25.4万 USD | 50.5万 USD | 16.9万 USD | — |
| 支払利息 | 2.1万 USD | 4.5万 USD | 58.9万 USD | 128.1万 USD | — |
| 減価償却費と償却費 | 10.5万 USD | 119.8万 USD | 293.2万 USD | 245.7万 USD | 22.6万 USD |
| 営業利益 | −2180.6万 USD | −4448.7万 USD | −6879.5万 USD | −9108.7万 USD | −5439.3万 USD |
| 純利益 | 40.1万 USD | 3979.1万 USD | −6417.5万 USD | −8898.3万 USD | −5034.7万 USD |
会社概要が更新されました 2026年10月12日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
評価サンプルは3件と限定的です
| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2026年1月2日 | 1:30 | — | — |
株式分割 | 2023年12月7日 | 1:15 | — | — |
発効済み 2026年1月2日
1:30
発効済み 2023年12月7日
1:15
この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
